Agent for external therapy of chronic recurrent inflammatory dermatopathies

FIELD: medicine.

SUBSTANCE: what is presented is the use of xenon in the form of an agent for external therapy of chronic recurrent inflammatory dermatopathies prepared by extra pure grade xenon saturation of a fatty base.

EFFECT: what is shown is considerable reduction of an inflammatory reaction on the second therapeutic day in such polygenic chronic inflammatory diseases, as psoriasis, atopic dermatitis, acne, acne rosacea, eczema.

4 ex

 

The invention relates to medicine and can be used in dermatology for the external treatment of chronic inflammatory skin diseases such as psoriasis, atopic dermatitis, acne, rosacea, eczema.

Psoriasis is one of the most common skin diseases. According to the statistics of this disease suffers from 1 to 8% of the world population. The frequent cases of severe forms that are difficult to treat and lead to disability in patients with frequent and prolonged recurrence (1).

Atopic dermatitis (AD) is one of the most common diseases encountered in all countries, in both sexes and in different age groups. According to numerous authors, the incidence varies from 6% to 20% per 1,000 population. The incidence of AD among residents of cities is higher than that of rural residents. In children blood pressure can occur in 1-4% of cases (10-15%) among the entire population, cohda as adults (0,2-0,5% of cases (2).

Acne (acne) is the most common chronic relapsing disease of the sebaceous glands and hair follicles that affects up to 85% of persons aged 12 to 25 years of age and 11% of persons over the age of 25 years (3).

Eczema is commonly found in relapsing disease of the skin, occurring at any age. Eczema is 30-40% of all skin related disease is evani (4).

Rosacea is a chronic, relapsing disease, usually of the skin, with polietiologic nature. Among dermatological diagnoses it is about 5% (5).

The Arsenal of tools used for the external treatment of chronic recurrent inflammatory skin diseases include common ointments, as sulphur ointment, papaverine cream, cream Uns, zinc ointment, etc.

Despite the achievements of domestic and foreign dermatology, the incidence of dermatitis remains very high. Currently, there is an increasing number of patients are resistant to traditional external therapy, and many dosage forms may not be used because of drug intolerance and formation of side-effects (6).

Object of the invention is the expansion of the means of the external treatment of skin diseases, the reduction of treatment time.

This object is achieved in that as a means of external therapy of chronic recurrent inflammatory diseases of the skin using xenon.

Previously known use of xenon as an inhalation anaesthetic with analgesic, antispasmodic, cardiotonic, neuroprotective, anti-stress, antihypoxic, immunostimulating, protivovospalitel the elegance, anabolic, neurohumoral, vasoplegic properties (7).

According to the Ministry of health of the Russian Federation No. 363 of 10.10.1999, Pharmacological Committee of Russia allowed the use of xenon in medical practice.

In the analysed literature, the use of xenon in clinical practice as a means for the external treatment of chronic recurrent inflammatory skin disease is not detected. Thus, in the claimed invention xenon exerts its new property, which leads to the achievement of a new technical result, and the proposed remedy is not adequate analogues, explicitly does not follow from the prior art and is not obvious to the expert.

The present invention can be used in medical practice as a new tool for the treatment of chronic recurrent inflammatory skin diseases, reduces the time of treatment of skin diseases.

Based on the foregoing should be considered as the invention with the relevant conditions of patentability of "Novelty", "Inventive step", "Industrial applicability".

The invention will be clear from the following description.

The proposed remedy for the external treatment is obtained by saturation of fatty basis xenon high purity (Xenon PTS", THE 2114-003-39791733-2002) methodology is ozonation. Bubbling routed through the bubblers of the porous glass flasks 1000 ml, in a volume of inert gas xenon, equal to the volume of a fatty basis to achieve equilibrium concentration. The ozonation process is carried out at a temperature of 35-40°C for 5-10 minutes with continuous stirring. Determination of the gas content in the medium for the external treatment is carried out using the method of gas-liquid chromatography.

The treatment is carried out by assigning to the affected skin areas of xenon in the form of outdoor therapy in the dose required for applying a thin layer of adequate lesion 1-2 times a day, morning and evening, for the treatment of various chronic recurrent inflammatory skin diseases (psoriasis, acne, atopic dermatitis, rosacea, eczema).

Example 1. Patient M., 56 years. Ds: Psoriasis vulgaris, numularia-plaque, spread, mixed, progressive stage, PASI=28, 2 points.

Topical treatment is applied on the left half of the body cream Uns. On the right half of the body cause the tool of external therapy in the form of a cream, enriched xenon. The base of the cream get the following formula:

Rp: Lanolini

Ol. Persicorum

Aq. destil. aa 50,0

M.D.S. cream Foundation for ozonation xenon.

Outdoor therapy is applied in equal amounts to poraj the nnye areas 2 times a day, morning and evening, together with the use of primary care.

The patient is thermometry pathological lesions, and assessment of the clinical picture index square of psoriatic lesions and the severity of the process PASI.

- 2 day outdoor therapy: right PASI=21.4 points, left PASI=26.2 points, indicators thermometry decreased to a greater extent on the right 0.53°C, left by 0.31°C.

- Day 7: the right PASI=9.2 points, left PASI=18.6 points. Because the severity of the clinical picture index PASI left decreased by 34%, and the right to 67,4%, which is 1.98 times more, as well as indicators of temperature, showing a significant reduction of the inflammatory reaction to the right, decided as a local therapy to apply the tool, enriched xenon.

Indicators of temperature (Δt°C)*
dayRight 1/2Left 1/2
135,7235,59
235,1935,28
732,9634,94
1630,9331,05

* - thermometry is performed on the largest psoriatic plaques legs. Measurements performed in 11 points pathological lesions using the apparatus of THIS Thermo Diagnostics and further calculating Δt°C.

- When discharged on the 16th day PASI is 3.6 points and, thus, PASI decreased by 87.2%of that meets the criteria for significant improvements.

Example 2. Patient S., 28 years. Ds: Atopic dermatitis, erythematous-lihenina form. Assessment using SCORAD index was 49. Sick since 3 years, notes the deterioration in the spring and autumn period.

Topical treatment is applied on the left half of the body papaverine cream 5%. On the right half of the body cause the tool of external therapy in the form of a cream, enriched xenon. The base of the cream get the following formula:

Rp: Lanolini

Ol. Persicorum

Aq. destil. aa 50,0

M.D.S. cream Foundation for ozonation xenon.

Outdoor treatment is applied in an equal amount to the affected areas 2 times a day, morning and evening, together with the use of primary care.

The patient is thermometry pathological lesions, and assessment of the clinical picture index evaluation of the cords is STI atopic dermatitis SCORAD.

- On the 2nd day of treatment: right SCORAD=40.5 points, left SCORAD=46 points; indicators thermometry decreased to a greater extent right on 0,69°C, left at 0,21°C.

- On the 7th day of treatment: right SCORAD=27.1 points, left SCORAD=36.7 points. Due to the fact that the evaluation index SCORAD left fell 25.1%, and the right 44.7%that of 1.78 times more, and indicators of temperature, indicating a decrease in inflammatory activity right at 2°C and left by 0.65°C, an increase of 1.35°C, it was decided as a local therapy to apply the tool, enriched xenon.

Indicators of temperature (Δt°)*
dayRight 1/2Left 1/2
135,6935,7
23535,49
733,6935,05
1832,2232,42
* - thermometry is performed on pathological foci flexor surface of the elbow joints. The measurement issue is lnewt 11 points pathological lesions using the apparatus of THIS Thermo Diagnostics and further calculating Δt°C.

At discharge on the 18th day evaluation of the clinical picture using SCORAD index is 8.6 points, thus SCORAD decreased by 82%, which meets the criteria for significant improvements.

Example 3. Patient, 30 years. Ds: Disgestrotical eczema of the hands. Evaluation index DASI=36 points, which corresponds to the criterion disgidroticheskuyu eczema severe.

Topical treatment is applied on the affected skin of the left hand of zinc ointment. On the right hand put the means of external therapy in the form of ointments, enriched xenon. Materials receive according to the following formula:

Rp.: Lanolini anhydrici

Vaselini aa 15,0

M.f. ung.

D.S. Basis ointments for ozonation xenon.

Outdoor treatment is applied in an equal amount to the affected areas 2 times a day, morning and evening, together with the use of primary care.

The patient is thermometry pathological lesions, and assessment of the clinical picture index of the area affected and the severity of the disease when disgestrotical eczema DASI.

- On the 2nd day of treatment: right DASI=24 points, left DASI=36 points; indicators thermometry decreased to a greater extent right on 1,38°C, left by 0.19°C.

- On the 7th day of treatment: right DASI=6 points left DASI=12 points. Due to the fact that the evaluation index DASI right decreased by 83.3%, left 66.7%, which is 1.25 times more, and pokazateli thermometry on the right indicate the reduction of inflammatory activity by 2.57°C, and on the left of 1.05°C, an increase of 1.52°C, resolved as external therapy to apply the tool in the form of ointments, enriched xenon.

Indicators of temperature (Δt°)*
dayRight 1/2Left 1/2
036,0335,95
234,6535,76
733,4634,9
2131,3731,35
* - thermometry is performed on abnormal foci of shibatani surface of the elbow joints. Measurements performed in 11 points pathological lesions using the apparatus of THIS Thermo Diagnostics and further calculating Δt°C.

At discharge on the 21 day evaluation of the clinical picture index DASI is 1 point, so DASI decreased by 97%, which meets the criteria for significant improvements.

Example 4. Patient E., 20 years. Ds: Acne, papules-pustular form, severe. Sick during the 6 years. Previously used drugs topical retinoids, antibiotics, benzoyl peroxide. Significant improvements have not occurred.

Topical treatment is applied on the left half of the face, neck, back, chest, 10% sulfur ointment. On the right half of the skin of these areas cause the tool of external therapy in the form of ointments, enriched xenon. Materials receive according to the following formula:

Rp.: Lanolini anhydrici

Vaselini aa 15,0

M.f. ung.

D.S. Basis ointments for ozonation xenon.

Outdoor treatment is applied in an equal amount to the affected areas 2 times a day, morning and evening, together with the use of primary care.

The patients were thermometry morphological elements, as well as evaluation of the clinical picture.

- On the 2nd day of treatment: right papules much settled, turned pale; left speakers are not marked.

- Day 7: right - morphological elements of an inflammatory nature was allowed to stagnant spots pale pink color, fresh skin rash no, left - single papules slightly settled, remains hyperemia elements arose 2 fresh papular element on the skin projection of the lower jaw; the indicators thermometry indicate the reduction of inflammatory activity in the skin right at 3.9°C, left at 0.7°C, which 3,21°C more, and therefore decided in quality is TBE external therapy to apply the tool in the form of ointments, enriched xenon.

Indicators of temperature (Δt°)*
dayRight 1/2Left 1/2
0of 35.2735,13
234,1534,83
732,8834,43

* - Thermometry is performed on a papular elements of the facial skin. Measurements are 6 points on the right half of the face and 6 points on the left half using the apparatus of THIS Thermo Diagnostics and further calculating Δt°C.

At discharge 30 day observed decrease of inflammatory cells by 50%, which meets the criteria for clinical improvement. After 6 months of therapy, which is applied to the xenon in the form of ointments, regression of the clinical picture was more than 75%, which meets the criteria for significant improvements.

When evaluating the effectiveness of treatment of patients with acne by means of external therapy, obocaman the m-xenon, under the proposed method, we obtained the following results:

- in 25.7% of patients reported a significant reduction of the inflammatory response on the 2nd day of use of xenon in the form of ointments;

74.3% on the 7th day is the resolution of inflammatory cells;

in 83% after 14 days of application do not arise fresh elements.

The present invention is applied in 26 patients, and obtained the technical result consists in the reduction of treatment time.

Sources of information

1. Milevsky YEAR, Pesterev PN. Psoriatic arthritis. - 1996

2. Volkov E.N. Atopic dermatitis. The attending physician. - 2006 - No. 9.

3. Adaskevich VP Acne vulgar and pink. - 2005

4. Skripkin J.K. Skin and venereal disease. - 1995

5. Potekaev NN. Acne and rosacea. - 2007

6. Sagmeister IA, dovzhanskiy SR Treatment of skin diseases. 1990 -

7. Suslov NI, Spizman M.N., Potapov V.N. The use of xenon in medicine. - 2009

The use of xenon in the form of funds for external therapy of chronic recurrent inflammatory skin diseases, obtained by saturation of fatty basis xenon purity.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to new heteroaryl compounds of general formula (I) and their pharmaceutically acceptable salts possessing the properties of protein kinase inhibitor, such as mTOR, IKK-2, Tyk2, Syk-kinase. In formula (I) R1 represents substituted or unsubstituted C1-8alkyl, substituted or unsubstituted aryl, specified in phenyl, substituted or unsubstituted 5-6-member heteroaryl with 1-3 nitrogen atoms in a cycle specified in pyridine, pyrazole, indole, indazole, triazole, benzimidazole, 2-(1H-imidazo-[4,5-b]pyridine, substituted or unsubstituted 5-7- member cycloalkyl or substituted or unsubstituted heterocycloalkyl specified in pyrrolidinyl; -X-A-B-Y- taken together form -N(R2)CH2C(O)NH-, -N(R2)C(O)CH2NH-, -N(R2)C(O)NH-, -N(R2)C=N- or -C(R2)=CHNH-; L represents a direct bond, NH or O; R2 represents substituted or unsubstituted C1-8alkyl, substituted or unsubstituted aryl specified in phenyl, tetrahydronaphthalene, unsubstituted 5-7- member mono- or 8- member bicycloalkyl; and R3 and R4 independently represent H or C1-8alkyl. The substitutes in the substituted groups are specified in one or more halogen, C1-8alkyl, hydroxyl, amino, nitro, thiol, C1-4alkyl thioether, cyano, carboxyl, C1-4alkyl ester, halogen alkyl, C6cycloalkyl or heteroaryl specified in pyridyl, triazole, O-lower alkyl, aryl specified in phenyl, phenyl-lower alkyl, CO2CH3, CONH2, OCHF2, CF3 or OCF3 groups wherein CONH2 group may be substituted by cyclohexyl.

EFFECT: compounds can find application for treating or preventing cancer, inflammatory pathological conditions, metabolic pathological conditions.

24 cl, 8 dwg, 2 tbl, 169 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel tetrahydroisoquinoline derivatives of general formula (I) or pharmacologically acceptable salts thereof, where R1 is a phenyl aminocarbonyl group which can be substituted with 1-3 groups independently selected from a substituting group A, a heteroaryl aminocarbonyl group, where the heteroaryl is pyridine, pyrazine, thiazole, pyrazole or isoxazole, which can be substituted with 1 group selected from a substituting group A, benzoxazol-2-yl group, which can be substituted with 1 group selected from a substituting group A, benzothiazol-2-yl group, (C1-C6 alkyl which can be monosubstituted with a C3-C6 cycloalkyl group), aminocarbonyl group, (C3-C6 cycloalkyl)aminocarbonyl group or adamantyl aminocarbonyl group; R2 independently represents a C1-C6 alkyl group; R3 is a heterocyclic group, where the heterocycle is oxazole, oxadiazole, pyrazole, isoxazole or tetrazole, which can be substituted with 1 group selected from a substituting group A, a group of formula -C(=O)-O-R4, or a group of formula -C(=O)-N(R5)R6; R4 is a hydrogen atom, a C1-C6 alkyl group which can be substituted with 1-2 groups independently selected from a substituting group B; R5 is a hydrogen atom, a C1-C6 alkyl group which can be substituted with 1 group selected from a substituting group B, a C3-C6 cycloalkyl group which is monosubstituted with a carboxyl group, or a heterocyclic group, where the heterocycle is tetrazole, which can be substituted with 1 group selected from a substituting group A; R6 is a hydrogen atom or a C1-C6 alkyl group; in those cases when both R5 and R6 represent a C1-C6 alkyl group, which can be substituted with 1 group selected from a substituting group B, their carbon atoms can be bonded to each other to form a 5-member saturated ring; X is an oxygen atom, a methylene group, a group of formula -NH-, a methylene group which is monosubstituted with a C1-C6 alkyl group, or a group of formula -N(R7)-; R7 is a C1-C6 alkyl group; L is a single bond, a methylene group, a 1,1-dimethylmethylene group, an ethylene group, a group of formula - CH=, or a methylene group which is monosubstituted with a C1-C6 alkyl group; … denotes a single bond or a double bond (however, … denotes a single bond when L is a group of formula -CH=); m equals 1 or 2; n equals 0 or 1; substituting group A is a group of substitutes selected from a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a C1-C6 alkoxy group, a C1-C6 halogenated alkoxy group, a C1-C6 alkylthio group, a carboxyl group, a di-(C1-C6 alkyl)amino group, a cyano group, a hydroxy group, a C1-C6 alkylthionyl group and an oxo group; and substituting group B is a group of substitutes selected from a carboxyl group and a hydroxy group. The invention also relates to a pharmaceutical composition based on the compound of formula (I), use of the compound of formula (I) and a method of treating and/or preventing a disease.

EFFECT: obtaining novel tetrahydroisoquinoline derivatives, having excellent inhibiting action on acyl-coenzyme A: diacylglycerol-acyltransferase and excellent food intake suppression.

31 cl, 113 ex

Adhesive plaster // 2474418

FIELD: medicine.

SUBSTANCE: invention refers to medicine. What is described is an adhesive plaster containing an elastic carrier and an adhesive layer applied on at least one side of the carrier wherein the elastic carrier contains a woven material knitted by stocking stitch on both sides, containing two or more lines of wavy multifilament PET yarns; the adhesive layer contains 25 to 50 wt % of a liquid organic ingredient and 25 to 50 wt % of a thermoplastic elastomer in relation to total weight of the layer, and contains 10 wt % or more of methyl salicylate as a liquid organic ingredient in relation to total weight of the layer, and a dynamic modulus of elasticity (G') of the adhesive layer makes 30000 to 75000 Pa at 10 rad/s and 37°C.

EFFECT: adhesive plaster possess the improved properties of drug release and skin absorption.

6 cl, 5 dwg, 6 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to immunology and biotechnology. There are presented versions of C3b antibodies each of which is characterised by the presence of six CDR and does not bind C3. What is described is a pharmaceutical composition on the basis of the antibody and a set used for prevention and treatment of a complement-related disorder.

EFFECT: use of the invention provides new C3b antibodies, Fab fragment of which inhibits an alternative complement cascade with lC50 approximately 100 nM that can find application in medicine for prevention and treatment of the complement-related disorder, eg an inflammatory or degenerative disease.

29 cl, 26 dwg, 1 tbl, 11 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed is application of tapentadol for manufacturing medication for treatment of pain caused by osteoarthrosis, in which at the beginning of treatment amount of taken in tapentadol is gradually increased in order to avoid side effects (titration from 25 mg two times per day to 200 mg two times per day).

EFFECT: reduction of prevalence of treatment side effects: day drowsiness, nausea, vomiting, dizziness and dry mouth.

13 cl, 4 dwg, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel imidazole derivatives of formula where A is pyridinyl; and B is a condensed ring system consisting of: a. a phenyl ring bonded to a molecular residue, b. a second heterocyclic 5- or 6-member ring which is condensed with the phenyl ring, and has one nitrogen or oxygen atom, and to tautomeric forms thereof.

EFFECT: obtaining novel imidazole derivatives which are antagonists of adrenergic receptors.

6 cl, 1 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to the chemical and pharmaceutical industry and specifically to an agent which is 13-isopropyl-4,10-dimethyldodecahydro-13,16-epoxyoxireno[2,3]naphtho[2,1-d][1,2]dioxycin-4-carboxylic acid of formula:

EFFECT: low toxicity, marked combination of anti-inflammatory and anti-ulcer activity.

1 cl, 1 ex, 2 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to bicyclosulphonyl acid (BCSA) compounds of formula: where: where each of -Rpw, -Rpx, -RPY, and -RPZ independently denotes H or -RRS1; each -RRS1 independently denotes -F, -Cl, -Br, -I, -RA1, -CF3, -OH, -OCF3 or -ORA1; where each RA1 independently denotes C1-4alkyl, phenyl or benzyl; and additionally, two neighbouring -RRS1 groups can together form -OCH2O-, -OCH2CH2O- or -OCH2CH2CH2O-; -RAK independently denotes a covalent bond, -(CH2)- or -(CH2)2-; -RN independently denotes -RNNN, or -LN-RNNN; the rest of the values of the radicals are given in claim 1, which act as inhibitors of inhibitors of tumor necrosis factor-α converting enzyme (TACE).

EFFECT: compounds are useful in treating TNF-α mediated conditions.

36 cl, 303 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula (I) , where Ar denotes each of R2, R3, R4, R5, R4' and R5' denote hydrogen; A denotes C(O); D denotes oxygen or NR8; E denotes CR63R64CR65R66; R63 and R64 denote hydrogen; R65 and R66 independently denote hydrogen or C1-4alkyl; k equals 0; m equals 1; R6 denotes a group -(X)p-Y-(Z)q-R10, or R6 denotes α- or β-branched C3-6alkyl (optionally substituted with C6cycloalkyl); X and Z independently denotes a C1-4alkylene group; p and q are independently equal to 0 or 1; Y denotes a bond; R8 denotes hydrogen; R10 denotes hydrogen or a saturated 5-7-member ring system; R7 denotes a 6-member aromatic ring, optionally substituted with a halogen, carboxyl, C1-6alkyl, C1-2alkoxy or a 5-member heteroaromatic ring (which is optionally substituted with C1-6alkyl); or a pharmaceutically acceptable salt thereof. Compounds of formula (I) or a pharmaceutically acceptable salt thereof are used to produce a medicinal agent for treating respiratory distress syndrome (ARDS), pulmonary emphysema, bronchitis, bronchiectasis, chronic obstructive pulmonary disease (COPD), asthma or rhinitis.

EFFECT: high efficiency of using said compounds.

7 cl, 1 tbl, 102 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula (IX) wherein radicals and symbols have values given in the claim, and pharmaceutically acceptable salts or tautomers thereof. Said compounds are inhibitors of poly(ADP-ribose)polymerase (PARP) and can be used to treat cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitisers for cancer treatment. The invention also relates to a pharmaceutical composition containing said compounds, use of said compounds and a method of treating said diseases.

EFFECT: high efficiency of using the compounds.

10 cl, 18 ex

FIELD: medicine.

SUBSTANCE: method relates to medicine, particularly to dermatology, and may be applied in treating psoriasis vulgaris. For this purpose, a patient is exposed to narrow-band medium-wave ultraviolet (UV therapy) at wave length 311 nm. It is combined with introducing liptonorm 10 mg once a day for 21-28 days. The UV therapeutic course makes 10 procedures.

EFFECT: method provides fast and prolonged clinical remission of the disease, as well as reduced side effects of the therapy due to the specified UV exposure mode and liptonorm introduction ensuring high photosensitising effect.

1 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to solid forms of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulphonylethyl]-4-acetylaminoisoindoline-1,3-dione of formula (I) inhibiting TNF-α or PDE4 production that enables using them in treating psoriasis.

EFFECT: producing an agent for treating psoriasis.

36 cl, 14 tbl, 33 dwg, 14 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a pharmaceutical composition for local application containing fusidic acid within the range of 1 wt % to 5 wt % and mometasone within the range of 0.05 wt % to 2 wt % and a pharmaceutically acceptable carrier to be applied in treating or preventing inflammatory dermatoses caused by a secondary bacterial infection in a patient.

EFFECT: invention provides effective elimination of secondary bacterial infections in dermatologic injuries.

11 cl, 8 ex, 6 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new compounds of formula (I) and its pharmaceutically acceptable salts possessing dihydroorotate dehydrogenase inhibitory ability, to a based pharmaceutical composition, to application thereof in preparing a drug compound and to a combined preparation containing the presented compounds and the other active compound (I) in effective amounts wherein both groups G1 mean CRC, G2 mean a nitrogen atom or group CRd, of the groups G3 and G4 mean a nitrogen atom and the other one means group CH, M means a hydrogen atom or a pharmaceutically acceptable cation, while R1, R2, Ra, Rb, Rc and Rd have the values specified in the patent claim.

EFFECT: preparing pharmaceutically acceptable salts possessing dihydroorotate dehydrogenase inhibitory ability.

25 cl, 115 ex, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to method of obtaining said salts, to pharmaceutical composition, containing said salts, and to application of salt for preparation of medication for treatment, prevention or relief of one or several symptoms of disease, mediated by CRTH2, associated with eosinophils, basophils, where disease is selected from asthma, allergic asthma, asthma of physical effort, allergic rhinitis, atopic dermatitis, contact hypersensitivity and hyper IgE syndrome.

EFFECT: invention relates to novel pharmaceutically acceptable salts, containing pharmaceutically acceptable amine, selected from ethylenediamine, piperazine, benzathine or choline and {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5yl}acetic acid.

43 cl, 21 dwg, 4 tbl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to novel crystalline forms I, II and amorphous form of {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl}acetic acid.

EFFECT: invention relates to pharmaceutical composition, containing crystalline form I of compound and to application of crystalline form I for treatment, prevention or relief of one or more symptoms of disease, mediated by CRTH2, associated with eosinophils, basophils, where disease is selected from asthma, allergic asthma, asthma, induced by physical effort, allergic rhinitis, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity.

16 cl, 11 dwg, 8 tbl,11 ex

FIELD: medicine.

SUBSTANCE: what is described is a composition for topical application which contains a continuous phase and at least one disperse phase with said composition containing at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue.

EFFECT: composition is characterised by better skin penetration or better stability.

27 cl, 3 dwg, 17 ex

FIELD: medicine.

SUBSTANCE: method of treating psoriasis. The invention refers to medicine, specifically to dermatology, and may be used for treating the patients suffering psoriasis. That is ensured by conducting detoxification, hyposensitising therapy, prescribing antihistamine preparations, vitamins, cytostatics, physiotherapeutic therapy, ointment applications. The conducted therapy is combined with additionally prescribed oral 40% alcoholate (1:10) containing herbal phytoecdysteroids in mass fractions 50 drops 3 times a day 15 minutes before meal daily for 30 days: Rhaponticum carthamoides roots and rhinzomes - 3, pot marigold blossom - 1, wild camomile blossom - 1.

EFFECT: method enabled considerably improved therapeutic effect in the patients due to evident immunomodulating, adaptogenic, sedative and anti-inflammatory effects of herbal phytoecdysteroids.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to dermatology and can be applied for external treatment of psoriatic onychodystrophy. For this purpose mixture of gel tisol and ointment daivonex is applied on nidus of affection in ratio 1:2 with following keeping under adhesive plaster during 8-10 h two times per day. Course of treatment constitutes not less than 14 days.

EFFECT: method ensures reduction of treatment terms and duration of remission and obtaining high therapeutic effect.

1 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry, and concerns preparing an agent for treating various dermatopathies: psoriasis, eczema, atopic dermatitis, ulcers incl. trophic and other diseases accompanied by inflammation or skin flaking. According to the first version, the composition contains ethoxylated alcohol, glycerol monostearate, higher fatty alcohols C16-C18 and cocoglycerides, as well as glycerol, olive oil and water. According to the other versions, it contains naphthalan oil or pentoxifylline or urea. All the versions provide a liposomal form of the composition improving healing, soothing and trophic effects.

EFFECT: composition is hypoallergic, easy-to-use.

12 cl, 8 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely surgery, and may be used for treating patients with trophic ulcers. That is ensured by the sequential intravenous drop-by-drop introduction of a mixture containing 5% glucose 200 ml, 0.5% Novocaine 50 ml, 25% magnesium sulphate 5 ml; that is followed by the introduction of a mixture containing 0.9% normal saline 200 ml, 2% pentoxifylline 5 ml and the introduction of a mixture containing rheopolyglucin 200 ml, 5% ascorbic acid 5 ml, 1% nicotinic acid 1 ml.

EFFECT: method enables stimulating trophic wound healing ensured by improved microcirculation and clinical course of metabolic processes.

1 ex

Up!